Pyxis Oncology
PYXS
51 hedge funds and large institutions have $15.8M invested in Pyxis Oncology in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 11 closing their positions.
1,100% more call options, than puts
Call options by funds: $24K | Put options by funds: $2K
2.05% more ownership
Funds ownership: 17.81% → 19.85% (+2%)
3% more capital invested
Capital invested by funds: $15.4M → $15.8M (+$399K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 54 → 51 (-3)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.21M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$285K |
| 3 |
Renaissance Technologies
New York
|
+$253K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$183K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$35.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$826K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$139K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$89K |
| 4 |
Two Sigma Investments
New York
|
-$48.4K |
| 5 |
Squarepoint
New York
|
-$44.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
51
ExodusPoint Capital Management
New York
| – | -$826K | -415,072 | Closed |
|
|
52
Squarepoint
New York
| – | -$44.9K | -22,556 | Closed |
|
53
SG Americas Securities
New York
| – | -$40K | -19,996 | Closed |
|
|
CSS
54
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$26.5K | -13,312 | Closed |
|
|
PCM
55
Prelude Capital Management
New York
| – | -$20.6K | -10,352 | Closed |
|
56
Simplex Trading
Chicago,
Illinois
| – | -$2.4K | -1,402 | Closed |
|
57
Fidelity Investments
Boston,
Massachusetts
| – | -$688 | -346 | Closed |
|
|
CMP
58
Coston McIsaac & Partners
Bar Harbor,
Maine
| – | -$195 | -114 | -79% |
|
|
AWA
59
Authentikos Wealth Advisory
Morgan Hill,
California
| – | -$42 | -21 | Closed |
|
PYXS Hedge Fund Activity: Q4 2023 in Review
51 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2023, worth a combined $15.8M — up 2.6% from $15.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PYXS and 9 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $1.21M. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $826K sold.
- 51 institutional investors held Pyxis Oncology (PYXS) as of Q4 2023, down from 54 in Q3 2023.
- Funds reported $15.8M of Pyxis Oncology stock for Q4 2023, up 2.6% quarter-over-quarter.
- 9 funds opened new Pyxis Oncology positions in Q4 2023 and 11 closed out, a net change of -2 holders.
- The largest Pyxis Oncology buyer in Q4 2023 was Aberdeen Group, an estimated $1.21M added.
- The largest Pyxis Oncology seller in Q4 2023 was ExodusPoint Capital Management, an estimated $826K sold.
Based on aggregated 13F filings for Q4 2023.